Figure 1.
Figure 1. OS for intermediate-risk AML by age group. Shown in black are patients ≤60 years of age (n = 1188); in red are patients >60 years of age (n = 493). These data were obtained from 1681 intermediate-risk AML patients treated within the AMLSG treatment trials AMLHD93, AMLHD98A (www.ClinicalTrials.gov identifier NCT00146120), AMLHD98B, AMLSG 06-04 (www.ClinicalTrials.gov identifier NCT00151255), and AMLSG 07-04 (www.ClinicalTrials.gov identifier NCT00151242).

OS for intermediate-risk AML by age group. Shown in black are patients ≤60 years of age (n = 1188); in red are patients >60 years of age (n = 493). These data were obtained from 1681 intermediate-risk AML patients treated within the AMLSG treatment trials AMLHD93, AMLHD98A (www.ClinicalTrials.gov identifier NCT00146120), AMLHD98B, AMLSG 06-04 (www.ClinicalTrials.gov identifier NCT00151255), and AMLSG 07-04 (www.ClinicalTrials.gov identifier NCT00151242).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal